Larimar Therapeutics (LRMR) Projected to Post Quarterly Earnings on Wednesday

Larimar Therapeutics (NASDAQ:LRMR) will likely be issuing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 14, 2025 at 12:00 AM ET.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.06. On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Larimar Therapeutics Price Performance

Shares of NASDAQ:LRMR opened at $4.29 on Wednesday. Larimar Therapeutics has a one year low of $1.61 and a one year high of $9.50. The company has a market cap of $355.13 million, a price-to-earnings ratio of -2.75 and a beta of 1.00. The firm has a 50 day simple moving average of $4.12 and a 200 day simple moving average of $3.18.

Analysts Set New Price Targets

Several research firms have recently issued reports on LRMR. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. JMP Securities dropped their price target on shares of Larimar Therapeutics from $22.00 to $18.00 and set a “market outperform” rating for the company in a research note on Friday, August 15th. Wedbush dropped their price target on shares of Larimar Therapeutics from $15.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, September 30th. Robert W. Baird dropped their price target on shares of Larimar Therapeutics from $10.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, September 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.71.

Insider Activity

In other Larimar Therapeutics news, Director James E. Flynn acquired 9,375,000 shares of Larimar Therapeutics stock in a transaction dated Thursday, July 31st. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $30,000,000.00. Following the completion of the acquisition, the director directly owned 9,538,945 shares of the company’s stock, valued at $30,524,624. This represents a 5,718.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. raised its position in Larimar Therapeutics by 114.7% in the second quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company’s stock worth $11,878,000 after acquiring an additional 2,195,923 shares during the period. Cerity Partners LLC bought a new stake in Larimar Therapeutics in the second quarter worth about $636,000. AQR Capital Management LLC bought a new stake in Larimar Therapeutics in the first quarter worth about $241,000. American Century Companies Inc. raised its position in Larimar Therapeutics by 7.8% in the second quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock worth $200,000 after acquiring an additional 5,001 shares during the period. Finally, Massar Capital Management LP bought a new stake in Larimar Therapeutics in the second quarter worth about $149,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.